![](/img/cover-not-exists.png)
NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma
Valencia-Sama, Ivette, Ladumor, Yagnesh, Kee, Lynn, Adderley, Teresa, Christopher, Gabriella, Robinson, Claire M., Kano, Yoshihito, Ohh, Michael, Irwin, Meredith S.Journal:
Cancer Research
DOI:
10.1158/0008-5472.CAN-19-3822
Date:
June, 2020
File:
PDF, 2.18 MB
2020